American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.
Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.
Article
PubMed
Google Scholar
King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164(7):1171–81.
Article
PubMed
Google Scholar
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.
Article
PubMed
Google Scholar
King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.
Article
PubMed
Google Scholar
Flaherty KR, King Jr TE, Raghu G, Lynch 3rd JP, Colby TV, Travis WD, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170(8):904–10.
Article
PubMed
Google Scholar
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
Article
PubMed
Google Scholar
Wells AU, Hirani N. Interstitial lung disease guideline. Thorax. 2008;63 Suppl 5:v1–v58.
Article
PubMed
Google Scholar
Flaherty KR, Andrei AC, King Jr TE, Raghu G, Colby TV, Wells A, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med. 2007;175(10):1054–60.
Article
PubMed
PubMed Central
Google Scholar
Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. New Engl J Med. 2012;366(21):1968–1977.
Article
Google Scholar
Merlin T, Lehman S, Hiller JE, Ryan P. The “linked evidence approach” to assess medical tests: a critical analysis. Int J Technol Assess Health Care. 2013;29(3):343–50.
Article
PubMed
Google Scholar
Yoshida K, Ando M, Sakata T, Araki S. Prevention of summer-type hypersensitivity pneumonitis: effect of elimination of Trichosporon cutaneum from the patients’ homes. Arch Environ Health. 1989;44(5):317–22.
Article
CAS
PubMed
Google Scholar
Selman M, Pardo A, King Jr TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012;186(4):314–24.
Article
CAS
PubMed
Google Scholar
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. New Engl J Med. 2006;354(25):2655–66.
Article
CAS
PubMed
Google Scholar
White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132(12):947–54.
Article
CAS
PubMed
Google Scholar
Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, et al. MYcophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease*. Chest. 2006;130(1):30–6.
Article
CAS
PubMed
Google Scholar
Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102(1):150–5.
Article
PubMed
Google Scholar
Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis–dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164(7):1182–5.
Article
CAS
PubMed
Google Scholar
Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143(3):814–24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR. Interstitial lung disease in primary Sjögren’s syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med. 1996;154(3):794–9.
Article
CAS
PubMed
Google Scholar
Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc. 2009;41(1):289–91.
Article
CAS
PubMed
Google Scholar
Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19.
Article
PubMed
Google Scholar
Ratner M. Landmark approvals in idiopathic pulmonary fibrosis. Nat Biotechnol. 2014;32(11):1069–70.
Article
CAS
PubMed
Google Scholar
Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, et al. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J. 2008;31(3):585–91.
Article
CAS
PubMed
Google Scholar
Aziz ZA, Wells AU, Hansell DM, Bain GA, Copley SJ, Desai SR, et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax. 2004;59(6):506–11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nicholson AG, Addis BJ, Bharucha H, Clelland CA, Corrin B, Gibbs AR, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax. 2004;59(6):500–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, et al. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(7):1023–30.
Article
PubMed
Google Scholar
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.
Article
CAS
PubMed
Google Scholar